The Oxt receptor (OTR) mediates the anti‐obesity effects of released Oxt from PVN.[23] Hence, we then i.c.v. pre‐administered the OTR antagonist, L‐368899, before rNrg4 delivery to HFD‐fed mice. Here, OXTR is linked to obesity due to melanocortin 4 receptor deficiency.